How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas

Shire's shares have been hurting for a long time now, in part because of the company's $32 billion Baxalta buy. (Shire)

Ahead of what’s sure to be a big week for struggling Shire, a prominent investor group is rehashing complaints over the company’s executive pay policy.

Pensions & Investment Research Consultants, which advises pension funds and others on how to vote at annual company meetings, called Shire chief Flemming Orkskov’s maximum potential bonus of 780% of salary “excessive,” Reuters reported, while pointing out that Ornskov actually saw his compensation fall last year.

Two other well-known shareholder advisory groups, though—ISS and Glass Lewis—both said they recommend investors vote in favor of all the proposals Shire will make at its annual general meeting next Tuesday, the news service noted.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Ornskov took home $5.3 million last year, down from $10.6 million the year prior. The decrease mirrored the slide Shire’s shares saw over the course of 2017, in part because of Ornskov’s long-sought—and unpopular—purchase of hemophilia specialist Baxalta.

PIRC’s griping revives complaints from two years ago, when nearly half of Shire shareholders voted against Shire’s remuneration setup. But sentiment rebounded last year, Reuters noted, with Shire garnering 93% support.

RELATED: Why are Shire's shares struggling? Some investors just don't understand, says CEO

Meanwhile, next week’s meeting will be just one of many big events for the Dublin drugmaker. It is set to report first-quarter earnings on Thursday, just one day after the deadline for suitor Takeda to either make a bid or walk away. The company has already announced its interest in buying Shire,

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.